• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Promising Role of Immunotherapy in Lung Cancer Treatment Emphasized at ELCC 2014


In the treatment of lung cancer, immunotherapy has come of age and is here to stay expert says at the 4th European Lung Cancer Conference.

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

Annals of Oncology

For decades, scientists and doctors thought immunotherapy — treatments that harness the immune system to fight a disease – was of marginal benefit in lung cancer, says ESMO spokesperson Jean-Charles Soria, Institute Gustave Roussy in Paris, France and Editor-in-Chief of .

However a new class of drugs known as “immunocheckpoint regulators” have shown huge potential, Soria says. New data on several of these drugs were presented at the conference.

Read the entire press release here:

http://bit.ly/1g2oeOF Source: European Society for Medical Oncology

Related Videos
dr amy laughlin
dr kathi mooney
dr saira jan
dr saira jan
Ted Okon, MBA, Community Oncology Alliance
Miriam J. Atkins, MD, FACP, Community Oncology Alliance/AO Multispecialty Clinic
Lalan Wilfongd, MD, US Oncology Network
Dr Carmen C. Solórzano
Crystal Denlinger
Related Content
© 2023 MJH Life Sciences
All rights reserved.